Testimonials

It is very nice to visit Lambda facility and thanks to warm welcome provided by all the teams. I can easily say one of the best CRO I ever visited. People here are wonderful and doing great job

Reputed Client of Israel

Awesome hospitality & fantastic office. All the best!

Reputed Client of Japan

Excellent hospitality and cooperation received throughout the audit. People are knowledgeable and extremely transparent. Looking for long time relation

Reputed Client of Asia

Facility is too good to conduct the BABE studies and adherence to protocol and quality assurance in conducting studies are meeting sponsor expectations and requirements.

Reputed Client of India

Facility is good, people r trained well and know the subject on which they r working. All the best.

Reputed Client of USA

Highly innovative and advanced research centre that possess bright future for the development of the country.

Reputed International Government Body

It is one of the best facility in India for BA/BE

Reputed Regulatory Authority

Lambda is a very professional CRO. All the staff here are experienced and very knowledgeable. I'm grateful for their accommodations and hospitality. The future, if we want to carry out BE study, we will ask Lambda help again.

Reputed Client of Europe

It was a really pleasant meeting with the PV department, and I am looking forward to the next visit.

Reputed Client of Europe

Amazing and best CRO I ever seen

Reputed Client of China

Company News

Company News

Home / Company News

Successful USFDA Analytical inspection - Lambda Canada Facility

25 May 2017

We take immense pleasure in informing the successful closure of the USFDA inspection of our Toronto facilities (Lambda Canada) conducted between 08th May 2017 to 12th May 2017. There were no inspectional observations and no FDA 483s' were issued for the ANDA submission studies inspected. Inspection was conducted as a part of routine Bioequivalent Clinical Bioresearch Monitoring (BIMO) inspection program of USFDA wherein analytical phases of multiple selected studies were reviewed by the inspector.

We have successfully completed a number of USFDA submission studies at all our global locations: Ahmedabad and Mumbai, India and Toronto, Canada (including First-To-File studies and Patient based Pharmacokinetic studies) over the last couple of years and undoubtedly, this is yet another feather in our cap as it reinforces our robust systems, processes and our overall commitment to Quality and International Regulatory Compliance in the Bioanalytical domain.

We seek this opportunity to thank you once again for your continued support and patronage of Lambda Therapeutic Research for your ANDA submissions.